Patient infected w/ HIV-1 w/o documented/clinically suspected resistance to integrase class 50 mg once daily. Patient infected w/ HIV-1 w/ resistance to integrase class (documented/clinically suspected) 50 mg bd. Adolescent 12 to <18 yr & at least 40 kg infected w/ HIV-1 w/o resistance to integrase class 50 mg once daily.
Discontinue use if signs or symptoms of hypersensitivity reactions develop. Opportunistic & other complications of HIV infection. Immune reactivation syndrome; osteonecrosis. Monitor liver biochemistries in patients w/ HBV &/or HCV co-infection. Co-administration w/ Mg- or Al-containing antacid, Fe & Ca supplements, multivit & inducing agents, etravirine (w/o boosted PIs), tipranavir/ritonavir, rifampicin, St. John's wort & certain anti-epileptics; metformin. May affect ability to drive & use machines. Severe hepatic impairment (Child-Pugh grade C). Women of childbearing potential should use effective contraception during treatment. Avoid use during 1st trimester of pregnancy. Lactation. Childn <12 yr or <40 kg.
Sign Out
